The abscopal effect induced by in situ-irradiated peripheral tumor cells in a murine GL261 brain tumor model by Zenkoh Junko et al.
The abscopal effect induced by in
situ-irradiated peripheral tumor cells in a
murine GL261 brain tumor model
著者 Zenkoh Junko, Gerelchuluun Ariungerel, Wang
Yuzi, Miwa Yoshihiro, Ohno Tadao, Tsuboi Koji
journal or
publication title
Translational Cancer Research
volume 6
number 1
page range 136-148
year 2017-02
権利 (C) Translational Cancer Research. All rights
reserved.
URL http://hdl.handle.net/2241/00145845
doi: 10.21037/tcr.2017.01.32
© Translational Cancer Research. All rights reserved. Transl Cancer Res 2017;6(1):136-148 tcr.amegroups.com
Introduction
It has been demonstrated that the localized irradiation 
of in vivo tumors alone can activate systemic antitumor 
immunity (1-3). This radiation-induced immune activation 
is termed “the abscopal effect (4)” and is thought to be 
initiated via “immunogenic cell death” caused by irradiation 
(5,6). It has been demonstrated that dying or newly dead 
tumor cells release damage associated molecular patterns 
(DAMPs) known as “eat me” or “find me” signals that 
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activate dendritic cells to recognize released tumor antigens 
(5,7-9). The resulting cytotoxic T-lymphocytes (CTLs) 
then circulate, recognize distant tumor cells, and kill 
them. Although this effect has been experimentally well 
established, rarely is the abscopal effect encountered in 
clinical practice (10,11). However, it remains controversial 
whether the abscopal effect is organ-independent as in 
some reported cases, brain metastases have appeared while 
primary and untreated metastases in other organs resolved 
(12,13). In particular, there have been no clinical reports in 
our search of the literature including two recent systematic 
clinical reviews (10,11), in which brain lesions have 
exhibited shrinkage or disappearance following radiotherapy 
to extracranial tumors.
The brain lacks a lymphatic system and is considered 
an immune-privileged site protected by the blood–brain 
barrier (BBB) at the normal condition (14), which inhibits 
the infiltration of circulating lymphocytes into the brain. 
However, when the BBB is disturbed by tumor formation, 
circulating lymphocytes may enter the brain through the 
disturbed sites (14,15). Therefore, it should be clarified 
whether or not circulating tumor specific lymphocytes act 
against challenged tumors in the brain.
One of the primary animal models used to examine the 
anti-tumor immune response in the brain is the orthotopic 
murine GL261 brain tumor model (16,17), in which ex 
vivo-irradiated tumor cells have been used for vaccination 
in various reports (16-18). This whole tumor cell vaccine 
inactivated by irradiation is assumed to activate cellular 
immunity by inducing the recognition of released tumor 
antigens by antigen-presenting cells, followed by the 
activation of tumor-specific cytotoxic T lymphocytes (CTL) 
in the lymph nodes. However, no studies have demonstrated 
if the irradiation of the “in situ” peripheral tumors can 
evoke an anti-tumor effect in the brain.
Therefore, we designed mouse experiments using the 
established GL261 brain tumor model to examine whether 
or not in situ-irradiated peripheral tumor cells can induce 
a protective, tumor-specific immune response in the brain, 
and to clarify the role of tumor specific lymphocytes in 
rejecting implanted tumor cells. This experimental mouse 
setting presented here is not directly assumed in clinical 
practice; however, examinations using the protocols for 
this model should help to understand how or under which 
conditions the in situ radiation-induced abscopal effect 
is evoked in the brain. In addition, these results may also 
apply to enhance the abscopal effect for the prevention of 
metastatic brain tumors.
Methods
GL261-mKO cells
The murine glioma cell line, GL261 (16,17) was provided 
free of charge by Dr. Masahiro Toda (Department of 
Neurosurgery, Keio University School of Medicine, 
Tokyo). GL261 cells were maintained in minimum 
essential Eagle’s medium (MEM; Sigma-Aldrich Japan) 
supplemented with 10% heat-inactivated fetal bovine 
serum (NICHIREI BIOSCIENCES INC., Tokyo, Japan), 
100 μg/mL streptomycin and 100 U/mL penicillin (Sigma-
Aldrich Japan, Tokyo, Japan). To monitor the size of 
implanted tumors using an in vivo imaging system (IVIS) 
(Perkin Elmer Inc., Waltham, MA, USA), the cells were 
stably transfected with a plasmid encoding the gene for 
monomeric Kusabira Orange protein (pCAG-hu2 mKO) 
using Lipofectamine LTX Reagent with PLUS™ Reagent 
(Thermo Fisher Scientific Inc. Waltham, MA, USA), 
followed by selection of positive clones with a media 
containing 800 μg/mL of G418 (Geneticin; Sigma-Aldrich 
Japan, Tokyo, Japan). Consequently, more than 10 G418-
resistant clonal cell lines stably expressing Kusabira Orange 
protein at various levels were identified by flow cytometry 
(FACSCalibur; Becton, Dickinson and Company Japan, 
Tokyo, Japan). Clonal cells expressing the maximum level 
of Kusabira Orange protein were selected and named 
“GL261-mKO.” The cells were cultured in MEM with 
10% FBS and antibiotics but without G418 continuously 
for three months, and subsequently, the fluorescent stability 
of GL261-mKO cells was confirmed using flow cytometry. 
The proliferative capacity and x-ray sensitivities of original 
GL261 cells and GL261-mKO cells were confirmed to be 
identical by triplicate growth analyses or standard colony 
formation assays. For inoculation of mice, GL261-mKO 
cells were harvested by trypsinization, washed twice with 
phosphate buffered saline and once with MEM without 
serum or antibiotics, and then resuspended in MEM 
without fetal bovine serum or antibiotics at a concentration 
of 6×105/5 μL for intracranial inoculation and 1×107/100 μL 
for subcutaneous inoculation.
Mouse intracranial and subcutaneous tumor model with 
GL261-mKO (Figure 1)
Albino C57BL/6 mice [B6(Cg)Tyrc-2J/J] were obtained from 
the Jackson Laboratory (Sacramento, CA, USA). All animal 
experimental procedures were conducted in accordance 
with a protocol approved by the Animal Experimentation 
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Figure 1 Characteristics of GL261-mKO mouse brain tumor model. (A) Growth curve of implanted the GL261-mKO cells inoculated in to 
the brain measured by an in vivo imaging system with representative pictures of in vivo imaging. The vertical and the horizontal lines indicate 
fluorescence intensity and days after inoculation, respectively. The error bars indicate standard deviations; (B) a chronological change of the 
body weight. The error bars indicate standard deviations; (C) a specimen of a tumor mass 46 days after inoculation, stained by hematoxylin-
eosin; (D) a survival curve of the 12 mice implanted with the GL261-mKO cells into the brain. A median survival time (MST) was 49 days. 
In this mouse brain tumor model, fluorescence from the intracranial tumor cells was detected approximately 40 days after inoculation, and 
all mice showed tumor engraftment without failure. As the tumors grew after a temporal decrease, the weight of the mice decreased.
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Committee of the Faculty of Medicine, University of 
Tsukuba. Eight- to 14-week-old male albino C57BL/6 
mice were anesthetized by intraperitoneal administration of 
pentobarbital (50 mg/kg), and the head was immobilized on 
a stereotactic operating unit (Narishige Co., Ltd., Tokyo, 
Japan). The scalp incision was made after preparation with 
70% ethanol, and a burr hole was made using a 26-G needle 
(TERUMO Corporation, Tokyo, Japan) 1.5 mm lateral to 
the midline and 3 mm anterior to the bregma of the skull. 
Subsequently, using a 10-μL Hamilton syringe (Sigma-
Aldrich Japan, Tokyo, Japan), 6×105 GL261-mKO cells in 
5 μL MEM were injected at a 2.5-mm depth from the 
surface of the skull. The cells were injected slowly for 
2 minutes, and the needle was left in place for 1 minute 
and slowly withdrawn thereafter. After confirmation of 
no overflow, the incision was manually sutured. In the 
subcutaneous model, the mice were anesthetized with 
isoflurane inhalation, and 1×107 GL261-mKO cells in 
100 μL MEM were then subcutaneously inoculated into 
the left femoral region using a 1-mL syringe (TERUMO 
Corporation) attached to a 27 G needle (TERUMO 
Corporation). In both the intracranial and subcutaneous 
tumor models, the tumor size was monitored by IVIS 
every 3 to 7 days for over 110 days following subcutaneous 
inoculation. Since the white hair of the mice disturbed 
the Kusabira Orange fluorescence, the tumor sites were 
depilated before IVIS detection. The mice were euthanized 
by cervical dislocation when severe neurological symptoms 
or weight reduction ≥20% appeared; this was in compliance 
with the “Guideline for Endpoints in Animal Study 
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Proposals” of the NIH (19). The intensity of Kusabira 
Orange fluorescence detected by IVIS was analyzed using 
Living Image 4.3.1 software (PerkinElmer Inc., Waltham, 
MA, USA).
Protocols
Immune protective protocol using in situ irradiated 
tumor cells as vaccine  
Ten days after the left femoral region of the mice was 
subcutaneously inoculated with GL261-mKO cells, the 
tumors were treated with localized radiation (20-Gy X-rays) 
using an X-ray generator (130 kV, 5 mA with 0.5 mm Cu 
and 0.1 mm Al, MBR-1520R; Hitachi Medical Co., Tokyo, 
Japan) with a custom-made 10-mm width brass collimator 
to expose only the subcutaneous tumors sites. Twenty-four 
days after irradiation, the brain was inoculated with GL261-
mKO cells. Both intracranial and subcutaneous tumors were 
monitored by IVIS. The mice were euthanized by cervical 
dislocation when severe neurological symptoms or weight 
reduction ≥20% appeared.
Immune protective protocol using ex vivo irradiated 
tumor cells for a comparison
GL261-mKO cel ls  were suspended in MEM at  a 
concentration of 1×107/100 μL and irradiated with 20-Gy 
X-rays (130 kV, 5 mA with 0.5 mm Cu and 0.1 mm Al, MBR-
1520R; Hitachi Medical Co., Tokyo, Japan). Within 30 
minutes of irradiation, the left femoral region of the mice was 
subcutaneously inoculated with GL261-mKO cells. Twenty-
four days after vaccination, the brain was also inoculated, and 
the cells were monitored by IVIS. The mice were euthanized 
by cervical dislocation when severe neurological symptoms or 
weight reduction ≥20% appeared.
Re-challenge with the same or a different tumor cell type
After a 110-day observation, the surviving mice without 
recurrence in the protective in situ vaccination protocol 
group were re-inoculated with 6×105 GL261-mKO cells or 
2.5×104 B16/BL6 cells (a syngeneic mouse melanoma cell 
line) in the brain. Mice were observed on alternate days 
until a point at which severe neurological symptoms or 
weight reduction ≥20% appeared.
Cluster of Differentiation 8 (CD8) + immunohistochemical 
staining
For immunohistochemical staining of the brain, tumor-
bearing mice were euthanized, and the brain was removed. 
Immediately, the brain was dissected and mounted in 
O.C.TTM compound (Sakura Finetek Japan Co., Ltd., 
Tokyo, Japan), and frozen gradually from −20 to −80 ℃. 
The frozen tissue was sliced into 6-μm-thick sections using 
a cryostat (CM1850; Leica Biosystems GmbH, Nussloch, 
Germany) and placed on precoated glass slides (Matsunami 
glass ind., ltd., Osaka, Japan). After drying for 10 minutes 
at room temperature, the tissue sections were fixed with 
acetone for 10 minutes at −20 ℃. The slides were rinsed 
twice with phosphate-buffered saline (PBS) for 5 minutes 
each at room temperature, followed by incubation with 
1% hydrogen peroxide in PBS for 5 minutes at room 
temperature to block endogenous peroxidase activity in 
the tissues. Following washing with PBS, the sections were 
blocked using Universal BlockerTM in Tris-buffered saline 
(TBS) (Thermo Fisher Scientific Inc. Waltham, USA) for 
30 minutes at room temperature. The slides were washed 
twice in PBS and then incubated with anti-CD8α (EP1150Y; 
Novus biologicals llc. Littleton, CO, USA) diluted in Can 
Get Signal immunoreaction enhancer solution-A (Toyobo 
Ltd. Osaka, Japan) for 1 hour at 25 ℃. Finally, the sections 
were stained with biotin–streptavidin using the LSAB®2 
system-HRP (DAKO Japan llc, Tokyo, Japan) according 
to the manufacturer’s instructions. When the specimens 
became brown in color, the reaction was stopped by rinsing 
with PBS. The specimens were stained with hematoxylin 
and eosin, dehydrated, penetrated, and covered with glass 
on the slides. Four mice with local control, 3 mice with 
brain tumors without pretreatment, and 2 mice with local 
failure were analyzed.
Enzyme-linked immunospot (ELISPOT) assay
Mice were euthanized by cervical dislocation, and the 
spleen was excised and ground using sterilized slide-
glasses. Following treatment with red blood lysis buffer, 
splenocytes were harvested, and single-cell suspensions 
were prepared in MEM. Splenocytes (2.5×106) were plated 
onto 96-well ELISPOT plates coated with purified anti-
mouse interferon (IFN)-γ antibody. The splenocytes 
were stimulated with or without GL261-mKO lysate. 
Following incubation at 37 ℃ with 5% CO2 for 24 hours, 
the ELISPOT assay was performed according to the 
manufacturer’s manual (Mouse IFN-γ ELISPOT Set; 
Becton, Dickinson and Company Japan). The number of 
spots were counted by eye. The results were derived from 
triplicates of each experiment.
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Survival analysis and statistics
Survival was analyzed using the Kaplan-Meier method, and 
statistical difference was determined using the log-rank 
test. A P value less than 0.05 was considered statistically 
significant.
Results
GL261-mKO brain tumor mouse model
The results of the intracranial tumor fluorescence detected 
by IVIS were shown in Figure 1. Fluorescence from the 
intracranial tumor cells was detected approximately 40 days 
after inoculation. All mice showed tumor engraftment 
without failure, and as the tumors grew after a temporal 
decrease, the weight of the tumor-bearing mice decreased. 
The hematoxylin-eosin staining of the brain removed from 
a tumor-bearing mouse demonstrated a well-circumscribed 
intracerebral tumor. The median survival time of the 
12 mice with intracranial tumors was 49 days (Figure 1). 
Effect of in situ- and ex vivo irradiated GL261-mKO cells
Sixteen mice were subcutaneously inoculated with GL261-
mKO cells in the left femoral region and were irradiated with 
20-Gy X-rays 10 days later. The dose of 20-Gy was selected 
in this study based on our previous studies in which the skin 
reaction was within a tolerable range and approximately 
half of the tumors were cured with this dose. Twenty-four 
days after irradiation, the brains were inoculated with the 
same tumor cell type. Among the 16 mice that underwent 
this protocol, 8 mice showed stabilization and eventual cure 
of the subcutaneous tumors by day 10 after irradiation. In 
contrast, in the remaining 8 mice, the subcutaneous tumors 
grew without shrinkage, or grew after temporal shrinkage 
followed by rapid growth from 40 to 50 days after X-ray 
irradiation (Figure 2). In all the 8 mice that were cured of 
subcutaneous tumors following irradiation (local control), 
inoculated GL261-mKO cells in the brain were completely 
rejected, and all the mice survived. In contrast, in all the 
8 mice that showed growth of tumors following irradiation 
(local failure), GL261-mKO cells inoculated in the brain 
were engrafted and grew very rapidly, and all mice did not 
survive (Figure 2). In Kaplan-Meier analysis, although the 
mice treated by the in situ vaccination started to die earlier, 
the median survival times of the 16 in situ vaccinated mice 
and 12 control tumor-bearing mice were 63 and 49 days, 
respectively. There was a significant difference between 
Figure 2 Two distinctly different growth patterns of tumors in the femoral region and in the brain after in situ-vaccination. (a) and (b): the 
tumors at the femoral region and in the brain in locally-controlled mice (n=8). (c) and (d): the tumors at the femoral region and in the brain 
in locally-failed mice (n=8). The error bars indicate standard deviation. Representative pictures of locally-failed and -controlled mice were 
shown on the right side. In all the 8 mice with cure of subcutaneous tumors (local control), inoculated GL261-mKO cells in the brain were 
completely rejected, and every mouse survived. In contrast, in all the 8 mice with re-growth of subcutaneous tumors (local failure), GL261-
mKO cells were engrafted and grew very rapidly in every mouse.
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Figure 3 (A) Survival curves of the mice after intracerebral implantation of the GL261-mKO cells. (a): the control mice with intracerebral 
tumors (n=12, MST =49 days). (b): the mice pre-treated by in situ-vaccination by localized irradiation (n=16, MST =63 days). There was 
a significant difference between them; (B) survival curves of the mice after intracerebral implantation of the GL261-mKO cells. (a): the 
control mice with intracerebral tumors (n=12, MST =49 days). (b): the mice pre-treated by in situ vaccination with local control (n=8, MST: 
not available). (c): the mice pre-treated by in situ vaccination with local failure (n=8, MST =38 days). There were significant differences 
between (a) and (b), (a) and (c), and (b) and (c). Although the mice treated by the in situ vaccination started to die earlier, the survival of the 
mice with in situ vaccination was significantly longer than that of control mice with intracerebral tumors. The survival of the mice treated 
by in situ vaccination was divided into 2 patterns based on the response of subcutaneous tumor, and the survival of locally-failed mice was 
significantly worse than that of control tumor-bearing mice.
these two cohorts in the log-rank test with a P value of 
0.047 (Figure 3A). The 8 mice with local control and the 8 
mice with local failure were analyzed separately using the 
Kaplan–Meier method. There was a significant difference 
between these two cohorts, with a P value of less than 
0.0001 in the log-rank test (Figure 3B). In addition, when 
comparing the 8 locally-failed mice and the 12 tumor-
bearing control mice, median survival times were 38 and 
49 days, respectively, and the survival of locally-failed mice 
was significantly worse than that of control tumor-bearing 
mice, with a P value of 0.034 (Figure 3B).  
With respect to ex vivo irradiated whole tumor cell 
vaccine, GL261-mKO cells were irradiated ex vivo with 
20-Gy X-rays, and were subcutaneously inoculated at the left 
femoral region of 7 mice at 15–30 minutes after irradiation. 
There was no tumor formation observed at the inoculation 
site. Among these 7 mice, 3 mice rejected the same tumor 
cells that had been inoculated in the brain 24 days after 
vaccination. The remaining 4 mice showed tumor cell 
engraftment in the brain on day 8 to 29. Consequently, the 
median survival time of the 7 vaccinated mice was 66 days. 
Kaplan–Meier analysis demonstrates significant prolongation 
of survival in this cohort with a P value of 0.038 compared 
with the 12 mice bearing intracranial tumors (Figure 4A). 
When comparing the survivals of mice treated with in situ- 
and ex vivo- irradiated vaccines, although the mice treated by 
the in situ vaccination started to die earlier, the final survivals 
were almost the same (P=0.927) (Figure 4B). 
Long-term survivors show a protective response to tumor 
re-challenge
To determine whether the long-term surviving mice 
acquired immunological memory following the protective 
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Figure 4 (A) Survival curves of the mice after intracerebral implantation of the GL261-mKO cells. (a): the control mice with intracerebral 
tumors (n=12, MST =49 days). (b): the mice pre-treated by ex vivo irradiated tumor cell vaccine (n=7, MST =66 days); (B) survival curves 
of the mice after intracerebral implantation with the GL261-mKO cells. (A) The mice pre-treated by ex vivo irradiated tumor cell vaccine 
(n=7, MST =66 days); (B) the mice pre-treated by in situ vaccination by localized irradiation (n=16, MST =63 days). There was no significant 
difference between them. The survival of the mice pre-treated by ex vivo irradiated tumor cell vaccine was significantly longer than that of 
the control mice bearing intracranial tumors (P=0.038). Comparing the survivals of mice treated with in situ- and ex vivo- irradiated vaccines, 
although the mice treated by the in situ vaccination started to die earlier, the final survivals were almost the same (P=0.927).
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protocol, the brains were re-inoculated with GL261-mKO 
or B16/BL6 cells 91–175 days after the former tumor 
implantation in the brain. With respect to the analysis of 
survival, mice that were re-inoculated in the brain with 
GL261-mKO cells survived without engraftment for over 
200 days. In contrast, all the mice that were inoculated 
with B16/BL6 cells showed neurological symptoms within 
two weeks of inoculation and were mortal. Kaplan–Meier 
analysis shows a significant difference between these two 
groups, with a P value of 0.0005 (Figure 5).
Infiltration of CD8+ CTLs
Using 4 mice that showed local control of the femoral tumor 
following irradiation, the brains were removed 7–14 days 
after intracerebral tumor inoculation. For comparison, 
brains of 2 locally-failed mice and 3 mice bearing tumor 
without pretreatment were removed 22–43 days after 
intracerebral tumor inoculation. Frozen sections were then 
immunohistochemically stained with an anti-CD8 antibody. 
In locally-controlled mice CD8+ cells were observed to be 
accumulated along the track of the needle and around the 
remaining intracerebral tumor cells (Figure 6). In contrast, 
CD8+ cells were scarcely observed in the locally-failed mice 
and the mice bearing brain tumor without pre-treatment 
(Figure 7). 
IFN-γ release from splenocytes
ELISPOT assay was performed to detect the IFN-γ 
released from splenocytes of the 9 treated mice: 4 mice with 
local control of the femoral tumor, 2 mice with local failure, 
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Figure 5 Survival curves of the mice after re-challenged by (A) 
GL261-mKO cells (n=6, MST: not available); and (B) B16/BL6 
cells (n=6, MST =15 days). There was a significant difference 
between them (P=0.0005).
Figure 6 Histological analyses of brain specimens of the mice pre-treated by in situ-vaccination with local control. (A) Hematoxylin-eosin 
staining; (B) immunohistochemical staining with anti-CD8 antibody with low and high magnification.
(a): mice re-challenged by Gl261-mKO cells
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and 3 mice with intracerebral tumor without any pre-
treatment. In every mouse with local control of the femoral 
tumor, the number of spots was significantly increased by 
antigen stimulation. Also, the numbers of spots after antigen 
stimulation in these mice were significantly larger than those 
in the mice with local failure (P=0.0002) and the control 
mice bearing intracerebral tumors (P=0.002) (Figure 8). 
In particular, the numbers of spots were significantly smaller 
and were not increased by antigen stimulation in the 2 mice 
with local failure, indicating that the anti-tumor immunity 
was almost completely suppressed in these mice. 
Discussion
GL261-mKO cells and the mouse brain tumor model 
Murine GL261 cells have been used for a standard 
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Figure 7 Histological analyses of brain specimens of the mice with intracerebral tumors without pre-treatment (A,B) and the mice with 
local failure after in situ-vaccination (C,D); (A,C) hematoxylin-eosin staining. The dotted lines indicate boundaries of the tumor; (B,D) 
immunohistochemical staining with anti-CD8 antibody with low and high magnification.
Figure 8 Results of ELISPOT assay. Black bars indicate the number of spots after antigen stimulation, and white bars indicate the number 
of spots without antigen stimulation. (A) The mice pre-treated by in situ-vaccination with local control (n=4); (B) the mice pre-treated by in 
situ-vaccination with local failure (n=2); (C) the control mice with intracerebral tumors (n=3).
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syngeneic mouse glioma model, in which a variety of 
immunotherapies have been investigated to date. GL261 
tumor cells reportedly have mutations in the p53 and K-ras 
oncogenes and express a low but detectable level of major 
histocompatibility complex (MHC) class I molecules (16,17), 
indicating that the cells are moderately immunogenic (16). 
In contrast, our GL261 cells demonstrated a high level of 
MHC class I expression, with a positivity ratio of over 90% 
(data not shown). Upon reviewing the literature reporting 
similar experiments, Szatmári et al. reported mean survival 
times of between 25–55 days, corresponding to the number 
of inoculated cells ranging from 1×105 to 1×102, indicating 
that their survival times may be shorter than ours despite 
the fact that they administered fewer inoculated cells (16). 
Because of the different passage methods (in vivo vs. in 
vitro passage) or long-term in vitro culture, the intrinsic 
immunogenicity may be altered, which can be one of the 
reasons for the substantial differences in the biological 
features between research groups. To monitor the volume 
of tumors using the in vivo imaging system, GL261 cells 
were transfected with a plasmid encoding the gene for 
monomeric Kusabira Orange protein (pCAG-hu2 mKO). 
The growth viability and radiosensitivity of GL261-mKO 
cells were identical to those of the native GL261 cells 
as observed in our previous experiments. Szatmári et al. 
reported a survival rate of approximately 40% with a 2 Gy 
irradiation, which is comparable to our results (16).
The in situ-irradiated tumor cells induce a protective 
abscopal effect if the mice are cured
Of the 16 mice that received the in situ vaccination, 8 
exhibited local tumor control following irradiation, and 
all mice rejected the same tumor cells challenged in the 
brain. In contrast, the other 8 mice that exhibited local 
failure following irradiation fell into an anergy state, and 
the tumor cells that were inoculated into the brain were 
engrafted and grew rapidly without exception (Figures 2,3B). 
In the survival analysis on the total 16 mice, the early 
loss is reflected by the 8 locally-failed mice with anergy 
state, and the late plateau part is reflected by the 8 locally-
cured mice (Figure 3A). Furthermore, the survival of the 8 
locally-failed mice was significantly worse than that of the 
12 control mice bearing intracranial tumors (Figure 3B). 
We consider that the tumor cells inoculated in the brain 
of none-vaccinated mice were attacked by the innate 
immune system first showing a temporary shrinkage of 
tumors, and survived tumor cells grew exponentially 
afterwards. In contrast, in locally-failed mice, not only the 
tumor specific immunity but also the innate immunity was 
probably disturbed by immune inhibiting factors released 
from recurrent tumors cells resulting in rapid growth of 
tumors. Also, this phenomenon in the locally-failed mice 
may be similar to a “phoenix rising” of the tumor, which is 
defined as an unexpected rapid regrowth of surviving tumor 
cells following irradiation (20,21). This phenomenon is 
reportedly induced by PGE2 produced by irradiated tumor 
cells, leading to rapid tumor regeneration (20).
Our results indicate that once the balance between 
local control and failure shifted to the control side, the 
mice successfully acquired systemic antitumor immunity. 
In contrast, when the balance tilted to the local failure 
side, the immune system fell into a state of anergy, and the 
immune response was suppressed. Although it is difficult to 
determine the specific factors associated with the mice that 
are locally cured or failed, the balance between the local 
control and failure may be dependent on the innate immune 
status of each host. Thus, an improvement of the peripheral 
tumor control rate may be associated with an increased 
rate of establishing systemic anti-tumor immunity. For this 
purpose, the concomitant use of local immune-stimulants 
(e.g., the local administration of cytokines or adjuvants), and 
radiation dose escalation within a safe range may be worth 
trying. 
A therapeutic model is more meaningful than a 
protective model for the analysis of immunotherapy. We 
have previously tested a protocol in which tumor cells were 
simultaneously inoculated into the subcutaneous tissue 
and into the brain, and only the subcutaneous tumors were 
irradiated; however, the abscopal effect on the tumor in 
the brain was not clearly noted (data not shown). In our 
opinion, it may be difficult to regress already engrafted 
brain tumor cells using only a distant abscopal effect 
induced by localized irradiation in this model. Moreover, 
this may be due to the insufficient immunogenicity of 
GL261. To further enhance the abscopal effect, research 
on combinations of different types of immunotherapy 
may be warranted. Recently, a combination of localized 
irradiation and the administration of an immune checkpoint 
inhibitor, a cytotoxic T lymphocyte antigen-4 (CTLA-4) 
antibody, has been reported to provide favorable results 
(22,23). Additionally, the enhancement of GL261 tumor 
cell immunogenicity has been attempted by using α-GalCer 
as an adjuvant (18) or via the transfection of cytokine-
producing genes to Gl261 cells (24,25) with favorable 
results.
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Effect of the ex vivo-irradiated tumor cell vaccine
The ex vivo X-ray-irradiated GL261-mKO cells acted as 
an effective tumor vaccine in this protective study. This 
is comparable to the results reported by Szatmári et al., 
in which an irradiated GL261 tumor cell vaccination was 
effective when administered 3 or 7 days before intracranial 
tumor transplantation. However, there was no significant 
effect when the vaccination was performed on the same day 
or 3 days following the intracranial transplantation (16).
It should be noted that a transfection of Kusabira Orange 
protein may alter the immunogenicity of the tumor cells 
used in our study. Rosenzweig et al. reported enhanced 
green fluorescent protein (eGFP)-induced MHC-restricted 
CTL responses mediated by CD8+ lymphocytes in rhesus 
macaques, and the eGFP-specific CTLs were able to lyse 
autologous CD34+ cells expressing eGFP (26). Although 
the immunogenicity of Kusabira Orange protein has not 
yet been clearly elucidated, we consider that the most of the 
immune response was induced by GL261 tumor antigens, 
since we confirmed that INF-γ production levels after 
stimulation with original GL261 and with GL261-mKO 
were identical by ELISPOT assay using splenocytes of 
cured mice (data not shown).
When comparing in situ and ex vivo irradiation for 
vaccination, in situ vaccination induces immunogenic tumor 
cell death with release of danger signals, which triggers a 
sequential systemic immunological response. In contrast, 
vaccination with ex vivo irradiated cells may be less effective 
because of less inflammation resulting in a lower level of 
danger signals released at the local site. Also, from a clinical 
point of view, surgery to remove tumor tissue is required 
for preparing whole tumor cell vaccine by irradiation. In 
contrast, surgical tumor removal is not necessary for in situ 
vaccination, thereby, it may be indicated for a wider range 
of tumors compared to vaccination with ex vivo.
Tumor re-challenge in the long-term surviving mice
Here, we demonstrated that immunological memory was 
established in the peripherally cured mice after irradiation. 
The re-challenged GL261-mKO cells were completely 
rejected in these mice. In contrast, the implanted B16/
BL6 melanoma cells grew rapidly and killed the mice 
with a median survival time of 15 days. In our preliminary 
experiments, the median survival time of the mice that were 
initially inoculated with the same B16/BL6 melanoma cells 
was 12 days. In addition, the survival time of these initially-
inoculated mice was significantly reduced compared to that 
of the mice with in situ vaccination (data not shown). It has 
been reported that the melanoma-associated antigens gp100 
and trp2 are shared with glioma cells (27). Thus, the CTLs 
induced by these common antigens may cause a growth 
delay of melanoma cells in in situ vaccinated mice. However, 
since there is a vast majority of different antigens, the 
inoculated B16/BL6 cells eventually survived and regrew.
Immune cell infiltration in the brain of tumor-bearing 
mice and ELISPOT assay
We demonstrated that the infiltration of CD8+ cells 
surrounding the tumor inoculation site was observed 
in the cured mice (Figure 6). Biollaz et al. reported that 
different immune cell infiltration patterns occurred 
in intracranial and peripheral glioma cells inoculated 
in a murine model (28). They observed an infiltration 
of CD4+ and CD8+ T cells in intracerebral tumors 
nine days following inoculation (28). Therefore, the 
temporal reduction in the inoculated tumor cells 
immediately after implantation may be caused by an 
innate immune response of non-specific immune cells 
(e.g., microglia). Nimmerjahn et al. and Mariani et al. 
reported that substantial numbers of activated microglia 
surrounding the inoculated tumors were noted by 7th day 
of inoculation (29,30). Those findings may indicate that 
surveying microglial cells initially respond as innate 
immune cells against tumor cell implantation, and 
subsequently, CD8+ T cells function to eliminate the 
inoculated tumor cells. A further analysis is necessary 
to clarify the interactions and roles of these two types, 
innate and acquired, immune cells.
In addition, using an ELISPOT assay with spleen cells, 
we showed that tumor antigen-specific IFN-γ release was 
significantly greater in locally-cured mice than in the failed 
mice (Figure 8). This supports the fact that mice with local 
control after the in situ vaccination acquired tumor-specific 
anti-tumor immunity.
Conclusions
In conclusion, the in situ-irradiated tumor cell vaccine 
was effective in this protective protocol using the GL261 
brain tumor model. In particular, X-ray irradiation to the 
peripheral subcutaneous tumors evoked a tumor-specific 
immune response (i.e., the protective abscopal effect) in the 
brain if the subcutaneous tumors were successfully cured. 
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This may indicate that the systemic anti-tumor immune 
balance largely depends on local tumor control following 
irradiation. 
Acknowledgements
We are indebted to Ms. Yoko Mori for her competent 
technical assistance. 
Funding: This work was supported in part by JSPS 
KAKENHI Grant Number JP16K10384.
Footnote
Conflict of Interest: Tadao Ohno is the CEO and a stock 
holder of Cell-Medicine, Inc.
Ethical statement: All animal experimental procedures were 
conducted in accordance with a protocol approved by the 
Animal Experimentation Committee of the Faculty of 
Medicine, University of Tsukuba (16-386).
References
1. Formenti SC, Demaria S. Radiation therapy to convert the 
tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 
2012;84:879-80.
2. Demaria S, Bhardwaj N, McBride WH, et al. Combining 
radiotherapy and immunotherapy: a revived partnership. 
Int J Radiat Oncol Biol Phys 2005;63:655-66.
3. Frey B, Rubner Y, Kulzer L, et al. Antitumor immune 
responses induced by ionizing irradiation and further 
immune stimulation. Cancer Immunol Immunother 
2014;63:29-36.
4. Postow MA, Callahan MK, Barker CA, et al. Immunologic 
correlates of the abscopal effect in a patient with 
melanoma. N Engl J Med 2012;366:925-31.
5. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic 
cell death and DAMPs in cancer therapy. Nat Rev Cancer 
2012;12:860-75.
6. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway 
combining calreticulin exposure and ATP secretion in 
immunogenic cancer cell death. EMBO J 2012;31:1062-79.
7. McBride WH, Chiang CS, Olson JL, et al. A sense of 
danger from radiation. Radiat Res 2004;162:1-19.
8. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin 
exposure dictates the immunogenicity of cancer cell death. 
Nat Med 2007;13:54-61.
9. Krysko O, Løve Aaes T, Bachert C, et al. Many faces of 
DAMPs in cancer therapy. Cell Death Dis 2013;16;4:e631.
10. Reynders K, Illidge T, Siva S, et al. The abscopal effect of 
local radiotherapy: using immunotherapy to make a rare 
event clinically relevant. Cancer Treat Rev 2015;41:503-10.
11. Abuodeh Y, Venkat P, Kim S. Systematic review of 
case reports on the abscopal effect. Curr Probl Cancer 
2016;40:25-37.
12. Ishiyama H, Teh BS, Ren H, et al. Spontaneous regression 
of thoracic metastases while progression of brain 
metastases after stereotactic radiosurgery and stereotactic 
body radiotherapy for metastatic renal cell carcinoma: 
abscopal effect prevented by the blood-brain barrier? Clin 
Genitourin Cancer 2012;10:196-8.
13. Stamell EF, Wolchok JD, Gnjatic S, et al. The abscopal 
effect associated with a systemic anti-melanoma immune 
response. Int J Radiat Oncol Biol Phys 2013;85:293-5.
14. Ransohoff RM, Brown MA. Innate immunity in the central 
nervous system. J Clin Invest 2012;122:1164-71.
15. Yang I, Han SJ, Kaur G, et al. The role of microglia in 
central nervous system immunity and glioma immunology. 
J Clin Neurosci 2010;17:6-10.
16. Szatmári T, Lumniczky K, Désaknai S, et al. Detailed 
characterization of the mouse glioma 261 tumor model 
for experimental glioblastoma therapy. Cancer Sci 
2006;97:546-53.
17. Maes W, Van Gool SW. Experimental immunotherapy for 
malignant glioma: lessons from two decades of research 
in the GL261 model. Cancer Immunol Immunother 
2011;60:153-60.
18. Hunn MK, Farrand KJ, Broadley KW, et al. Vaccination 
with irradiated tumor cells pulsed with an adjuvant that 
stimulates NKT cells is an effective treatment for glioma. 
Clin Cancer Res 2012;18:6446-59.
19. National Institutes of Health, Animal Research Advisory 
Committee. NIH Guidelines for Endpoints in Animal 
Study Proposals. (24 August 2016, date last accessed). 
Available online: https://oacu.oir.nih.gov/sites/default/
files/uploads/arac-guidelines/asp_endpoints.pdf
20. Li F, Huang Q, Chen J, et al. Apoptotic cells activate the 
"phoenix rising" pathway to promote wound healing and 
tissue regeneration. Sci Signal 2010;3:ra13.
21. Ng WL, Huang Q, Liu X, et al. Molecular mechanisms 
involved in tumor repopulation after radiotherapy. Transl 
Cancer Res 2013;2:442-8.
22. Yoshimoto Y, Suzuki Y, Mimura K, et al. Radiotherapy-
induced anti-tumor immunity contributes to the 
therapeutic efficacy of irradiation and can be augmented 
by CTLA-4 blockade in a mouse model. PLoS One 
148 Zenkoh et al. In situ irradiated tumor cell vaccine
© Translational Cancer Research. All rights reserved. Transl Cancer Res 2017;6(1):136-148 tcr.amegroups.com
2014;31;9:e92572.
23. Belcaid Z, Phallen JA, Zeng J, et al. Focal radiation therapy 
combined with 4-1BB activation and CTLA-4 blockade 
yields long-term survival and a protective antigen-specific 
memory response in a murine glioma model. PLoS One 
2014;9:e101764.
24. Lumniczky K, Desaknai S, Mangel L, et al. Local tumor 
irradiation augments the antitumor effect of cytokine-
producing autologous cancer cell vaccines in a murine 
glioma model. Cancer Gene Ther 2002;9:44-52.
25. Newcomb EW, Demaria S, Lukyanov Y, et al. The 
combination of ionizing radiation and peripheral 
vaccination produces long-term survival of mice bearing 
established invasive GL261 gliomas. Clin Cancer Res 
2006;12:4730-7.
26. Rosenzweig M, Connole M, Glickman R, et al. Induction 
of cytotoxic T lymphocyte and antibody responses 
to enhanced green fluorescent protein following 
transplantation of transduced CD34(+) hematopoietic 
cells. Blood 2001;97:1951-9.
27. Prins RM, Odesa SK, Li au LM. Immunotherapeutic 
targeting of shared melanoma-associated antigens in a 
murine glioma model. Cancer Res 2003;63:8487-91.
28. Biollaz G, Bernasconi L, Cretton C, et al. Site-specific 
anti-tumor immunity: differences in DC function, TGF-
beta production and numbers of intratumoral Foxp3+ 
Treg. Eur J Immunol 2009;39:1323-33.
29. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting 
microglial cells are highly dynamic surveillants of brain 
parenchyma in vivo. Science 2005;308:1314-8.
30. Mariani CL, Kouri JG, Streit WJ. Rejection of RG-2 
gliomas is mediated by microglia and T lymphocytes. J 
Neurooncol 2006;79:243-53.
Cite this article as: Zenkoh J, Gerelchuluun A, Wang Y, 
Miwa Y, Ohno T, Tsuboi K. The abscopal effect induced by 
in situ-irradiated peripheral tumor cells in a murine GL261 
brain tumor model. Transl Cancer Res 2017;6(1):136-148. doi: 
10.21037/tcr.2017.01.32
